Free tool
FDA Approval Tracker
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026Drugs@FDA last updated: Nov 18, 2026Methods & limitations
Matching approvals
298
2015 to 2026
Breakthrough
116
Accelerated
79
Priority review
229
Orphan
298
By year
NDAs and BLAs matching the filters.
- NDA
- BLA
View as table
| Year | NDA | BLA |
|---|---|---|
| 2015 | 14 | 7 |
| 2016 | 8 | 2 |
| 2017 | 17 | 5 |
| 2018 | 25 | 12 |
| 2019 | 17 | 6 |
| 2020 | 23 | 9 |
| 2021 | 20 | 7 |
| 2022 | 11 | 10 |
| 2023 | 19 | 11 |
| 2024 | 17 | 10 |
| 2025 | 19 | 5 |
| 2026 | 16 | 8 |
298 approvals
Newest first. Hover a badge for what it means.
- Klygefa (Gefurulimab) · Alexion PharmNov 13, 2026Original approval · BLA 761488NovelOrphan
To treat anti-acetylcholine receptor antibody-positive generalized myasthenia gravis
- Emcitate (Tiratricol) · Rare ThyroidSep 28, 2026
To treat peripheral thyrotoxicosis in patients with MCT8 deficiency
- Atebrioz (Zilurgisertib Fumarate) · MirumSep 25, 2026
To reduce the volume of total new heterotopic ossification in adults and pediatric patients 12 years and older with fibrodysplasia ossificans progressiva
- Lyrfigtu (Lirafugratinib Hydrochloride) · ElevarSep 23, 2026
To adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring a fibroblast growth factor receptor 2 gene fusion or other rearrangement
- Isembyld (Apitegromab-Mstn) · Scholar Rock INCSep 11, 2026
To treat spinal muscular atrophy in adults and pediatric patients 2 years of age and older who are currently receiving an SMN2-targeted treatment
- Pixclara (Floretyrosine F-18) · TelixSep 11, 2026
To use with positron emission tomography to differentiate recurrent or progressive glioma from treatment-related change in conjunction with other diagnostic evaluations
- Zanvastro (Zilganersen Sodium) · Ionis Pharms INCSep 3, 2026
To treat Alexander disease in pediatric and adult patients
- Mimrylo (Rusfertide Acetate) · Takeda Pharms AmAug 28, 2026
To treat erythrocytosis in adults with polycythemia vera
- Lisraya (Brepocitinib Tosylate) · Priovant TherapAug 27, 2026
To treat dermatomyositis in adults
- Rasonque (Daraxonrasib) · Revolution MedicinesAug 26, 2026
To treat metastatic pancreatic cancer
- Pasatru (Garetosmab-Grts) · Regeneron Pharmaceuticals, INCAug 19, 2026
To reduce new heterotopic ossification and clinician-assessed disease flare-ups in adults with fibrodysplasia ossificans progressiva
- Zenbexus (Iberdomide Hydrochloride) · Bristol Myers SquibbAug 13, 2026
To be used in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent
- Orzeyful (Oveporexton) · Takeda Pharms USAAug 5, 2026
To treat narcolepsy type 1
- Jideytro (Zidesamtinib) · NuvalentJul 22, 2026
To treat adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer after receiving a ROS1 kinase inhibitor
- Ambelvist (Gadoquatrane) · Bayer HealthcareJun 12, 2026
To detect and visualize lesions with abnormal vascularity, in conjunction with MRI
- Decnupaz (Pivekimab Sunirine-Pvzy) · Abbvie INCMay 27, 2026
To treat adults with blastic plasmacytoid dendritic cell neoplasm
- Hepcludex (Bulevirtide-Gmod) · Gilead Sciences INCMay 22, 2026Original approval · BLA 761468NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
To treat chronic hepatitis delta virus infection in adults without cirrhosis or with compensated cirrhosis
- Beqalzi (Sonrotoclax) · Beone Medicines USAMay 13, 2026Original approval · NDA 220711NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
To treat adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton's tyrosine kinase inhibitor
- Awiqli Flextouch (Insulin Icodec) · Novo Nordisk INCMar 26, 2026
- Avlayah (Tividenofusp Alfa-Eknm) · Denali Therapeutics Inc.Mar 24, 2026Original approval · BLA 761485NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
To treat certain individuals with Hunter syndrome (Mucopolysaccharidosis type II or MPS II)
- Lynavoy (Linerixibat) · InterceptMar 17, 2026
To treat cholestatic pruritus associated with primary biliary cholangitis
- Yuviwel (Navepegritide) · AscendisFeb 27, 2026
To increase linear growth in pediatric patients 2 years and older with achondroplasia with open epiphyses
- Loargys (Pegzilarginase-Nbln) · Immedica Pharma AbFeb 23, 2026Original approval · BLA 761211NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
To treat hyperarginemia in adults and pediatric patients two years and older with Arginase 1 Deficiency, in conjunction with dietary protein restriction
- Zycubo (Copper Histidinate) · Sentynl Theraps INCJan 12, 2026
To treat Menkes disease
- Yartemlea (Narsoplimab-Wuug) · Omeros CorpDec 23, 2025
To treat hematopoietic stem cell transplant-associated thrombotic microangiopathy
- Myqorzo (Aficamten) · CytokineticsDec 19, 2025
To treat symptomatic obstructive hypertrophic cardiomyopathy
- Hyrnuo (Sevabertinib) · Bayer HealthcareNov 19, 2025Original approval · NDA 219972NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
To treat locally advanced or metastatic non-squamous non-small cell lung cancer with tumors that have activating HER2 tyrosine kinase domain activating mutations in patients who received a systemic therapy
- Redemplo (Plozasiran Sodium) · ArrowheadNov 18, 2025
To reduce triglycerides in adults with familial chylomicronemia syndrome
- Komzifti (Ziftomenib) · KuraNov 13, 2025
To treat adults with relapsed or refractory acute myeloid leukemia with a susceptible nucleophosmin 1 mutation who have no satisfactory alternative treatment options
- Kygevvi (Doxecitine, Doxribtimine) · Ucb INCNov 3, 2025
To treat thymidine kinase 2 deficiency in patients who start to show symptoms when they are 12 years old or younger
- Ferabright (Ferumoxytol) · AzurityOct 16, 2025
- Jascayd (Nerandomilast) · Boehringer IngelheimOct 7, 2025
To treat idiopathic pulmonary fibrosis
- Palsonify (Paltusotine Hydrochloride) · CrineticsSep 25, 2025
To treat acromegaly in adults who had an inadequate response to surgery and/or for whom surgery is not an option
- Forzinity (Elamipretide Hydrochloride) · Stealth BiotherapsSep 19, 2025
To improve muscle strength in patients with Barth syndrome weighing at least 30 kg
- Wayrilz (Rilzabrutinib) · Genzyme CorpAug 29, 2025
To treat persistent or chronic immune thrombocytopenia that has not sufficiently responded to immunoglobulins, anti-D therapy, or corticosteroids
- Dawnzera (Autoinjector) (Donidalorsen Sodium) · Ionis Pharms INCAug 21, 2025
To prevent attacks of hereditary angioedema
- Modeyso (Dordaviprone Hydrochloride) · ChimerixAug 6, 2025
To treat diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy
- Sephience (Sepiapterin) · Ptc TherapJul 28, 2025
To treat hyperphenylalaninemia in patients with sepiapterin-responsive phenylketonuria, in conjunction with a phenylalanine-restricted diet
- Ekterly (Sebetralstat) · KalvistaJul 3, 2025
To treat acute attacks of hereditary angioedema
- Lynozyfic (Linvoseltamab-Gcpt) · Rengeneron Pharmaceuticals, Inc.Jul 2, 2025
To treat relapsed or refractory multiple myeloma after at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti CD38 monoclonal antibody
- Andembry (Garadacimab-Gxii) · Csl Behring LLCJun 16, 2025
To prevent attacks of hereditary angioedema
- Ibtrozi (Taletrectinib Adipate) · NuvationJun 11, 2025
To treat locally advanced or metastatic ROS1-positive non-small cell lung cancer
- Avmapki Fakzynja CO-Pack (Copackaged) (Avutometinib Potassium, Defactinib Hydrochloride) · Verastem INCMay 8, 2025Original approval · NDA 219616NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
To treat KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) after prior systemic therapy
- Imaavy (Nipocalimab-Aahu) · Janssen BiotechApr 29, 2025
To treat generalized myasthenia gravis
- Penpulimab-Kcqx (Penpulimab-Kcqx) · Akeso BiopharmaApr 23, 2025
In combination with either cisplatin or carboplatin and gemcitabine, to treat adults with recurrent or metastatic non-keratinizing nasopharyngeal carcinoma (NPC), or as a single agent while on or after platinum-based chemotherapy and at least one other prior line of therapy
- Qfitlia (Fitusiran Sodium) · Genzyme CorpMar 28, 2025
To prevent or reduce the frequency of bleeding episodes in hemophilia A or B
- Gomekli (Mirdametinib) · SpringworksFeb 11, 2025
To treat neurofibromatosis type 1 who have symptomatic plexiform neurofibromas not amenable to complete resection
- Grafapex (Treosulfan) · MedexusJan 21, 2025
For use in combination with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome
- Alhemo (Concizumab-Mtci) · Novo Nordisk INCDec 20, 2024
For routine prophylaxis to prevent bleeding episodes in hemophilia A and B
- Alyftrek (Deutivacaftor, Tezacaftor, Vanzacaftor Calcium) · Vertex Pharms INCDec 20, 2024
For the treatment of cystic fibrosis (CF) in patients 6 years of age and older
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.